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There is an obvious increasing interest in human mesenchymal stem cell (hMSC)-based therapies for 
regenerative medicine (e.g. neurology, cardiology, immunology, orthopaedics). At the beginning of May 2018, 
there were 253 registered clinical trials using hMSCs (www.clinicaltrials.gov). Despite the large number of 
current clinical studies, only 13 hMSC-based products have received regulatory approval. In order to efficiently 
manufacture hMSC-based products, not only must the targeted cell quantity and quality be taken into account, 
but the production costs must also be considered. In general, autologous and allogeneic stem cell products are 
characterized by similar upstream processing (USP), downstream processing (DSP), formulation, and fill & 
finish operations. Typical USP operations are manufacturing of the Master Cell Bank (MCB) and the Working 
Cell Bank (WCB), seed cell production, and subsequent cell expansion. The DSP steps include cell harvesting, 
cell detachment, cell separation, washing and concentration procedures, and medium exchange. However, 
before hMSCs can be administered as an Advanced Therapeutic Medicinal Product (ATMP), additional 
formulation, and fill and finish steps have to be carried out. The main differences between allogeneic and 
autologous manufacturing approaches are the number of therapeutic doses generated in each batch and the 
number of patients treated. Therefore, it is unsurprising that allogeneic therapies are the more cost-effective 
method in terms of hMSC production. Furthermore, various economic studies have demonstrated that USP and 
in particular, hMSC expansion, represent the main cost drivers when examining the entire manufacturing 
process. In order to achieve the high cell numbers of up to 1013 cells per batch needed in allogeneic hMSC 
manufacturing processes, manufacturers have to move away from traditional planar cultivation systems. Many 
reports over the last years have shown that instrumented, single-use bioreactors in combination with 
microcarriers are promising systems for this task.  
 
Even though different procedures and equipment for USP and DSP are already available and established for 
allogeneic production of hMSCs, various challenges still exist. Therefore, the authors intend to highlight the 
current state of the art of allogeneic hMSC manufacturing and show the current main process and regulatory 
challenges for USP and DSP operations.  
 
